U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C26H26N6O3
Molecular Weight 470.523
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of POSELTINIB

SMILES

CN1CCN(CC1)C2=CC=C(NC3=NC4=C(OC=C4)C(OC5=CC(NC(=O)C=C)=CC=C5)=N3)C=C2

InChI

InChIKey=LZMJNVRJMFMYQS-UHFFFAOYSA-N
InChI=1S/C26H26N6O3/c1-3-23(33)27-19-5-4-6-21(17-19)35-25-24-22(11-16-34-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)

HIDE SMILES / InChI

Molecular Formula C26H26N6O3
Molecular Weight 470.523
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
11.5 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
POSELTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
56.5 ng/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
POSELTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
186 ng/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
POSELTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
358 ng/mL
160 mg single, oral
dose: 160 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
POSELTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
65.8 ng/mL
30 mg 1 times / day steady-state, oral
dose: 30 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
POSELTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
201 ng/mL
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
POSELTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
84.8 ng × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
POSELTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
276 ng × h/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
POSELTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1040 ng × h/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
POSELTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2100 ng × h/mL
160 mg single, oral
dose: 160 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
POSELTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
368 ng × h/mL
30 mg 1 times / day steady-state, oral
dose: 30 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
POSELTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1347 ng × h/mL
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
POSELTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.6 h
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
POSELTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Substance Class Chemical
Created
by admin
on Mon Mar 31 23:09:21 GMT 2025
Edited
by admin
on Mon Mar 31 23:09:21 GMT 2025
Record UNII
D01E4B1U35
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
POSELTINIB
INN  
INN  
Official Name English
poseltinib [INN]
Preferred Name English
HM71224
Code English
Poseltinib [WHO-DD]
Common Name English
N-(3-((2-(4-(4-METHYLPIPERAZIN-1-YL)ANILINO)FURO(3,2-D)PYRIMIDIN-4-YL)OXY)PHENYL)PROP-2-ENAMIDE
Systematic Name English
LY3337641
Code English
2-PROPENAMIDE, N-(3-((2-((4-(4-METHYL-1-PIPERAZINYL)PHENYL)AMINO)FURO(3,2-D)PYRIMIDIN-4-YL)OXY)PHENYL)-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C124801
Created by admin on Mon Mar 31 23:09:21 GMT 2025 , Edited by admin on Mon Mar 31 23:09:21 GMT 2025
Code System Code Type Description
CAS
1353552-97-2
Created by admin on Mon Mar 31 23:09:21 GMT 2025 , Edited by admin on Mon Mar 31 23:09:21 GMT 2025
PRIMARY
EPA CompTox
DTXSID501112972
Created by admin on Mon Mar 31 23:09:21 GMT 2025 , Edited by admin on Mon Mar 31 23:09:21 GMT 2025
PRIMARY
INN
10235
Created by admin on Mon Mar 31 23:09:21 GMT 2025 , Edited by admin on Mon Mar 31 23:09:21 GMT 2025
PRIMARY
WIKIPEDIA
Poseltinib
Created by admin on Mon Mar 31 23:09:21 GMT 2025 , Edited by admin on Mon Mar 31 23:09:21 GMT 2025
PRIMARY
NCI_THESAURUS
C141273
Created by admin on Mon Mar 31 23:09:21 GMT 2025 , Edited by admin on Mon Mar 31 23:09:21 GMT 2025
PRIMARY
SMS_ID
100000174648
Created by admin on Mon Mar 31 23:09:21 GMT 2025 , Edited by admin on Mon Mar 31 23:09:21 GMT 2025
PRIMARY
PUBCHEM
56644522
Created by admin on Mon Mar 31 23:09:21 GMT 2025 , Edited by admin on Mon Mar 31 23:09:21 GMT 2025
PRIMARY
FDA UNII
D01E4B1U35
Created by admin on Mon Mar 31 23:09:21 GMT 2025 , Edited by admin on Mon Mar 31 23:09:21 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
IC50
TARGET -> INHIBITOR
IRREVERSIBLE INHIBITOR
IC50
TARGET -> INHIBITOR
IRREVERSIBLE INHIBITOR
IC50
TARGET -> INHIBITOR
IC50
OFF-TARGET->INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY